Aequus Pharmaceuticals Inc. (CVE:AQS) Director Buys C$11,400.00 in Stock
Aequus Pharmaceuticals Inc. (CVE:AQS) Director Buys C$11,400.00 in Stock
(Get Rating)Aequus Pharmaceuticals Inc. (CVE:AQS – Get Rating) Director Doug Janzen acquired 285,000 shares of the business's stock in a transaction on Wednesday, November 30th. The shares were purchased at an average price of C$0.04 per share, with a total value of C$11,400.00. Following the transaction, the director now owns 12,553,800 shares in the company, valued at approximately C$502,152.
董事道格·扬岑在11月30日星期三的一笔交易中收购了该公司28.5万股股票。这些股票是以每股0.04加元的平均价格购买的，总价值为11,400.00加元。交易完成后，董事现在拥有该公司12,553,800股，价值约502,152加元。
Doug Janzen also recently made the following trade(s):
道格·詹森最近还进行了以下交易：
- On Sunday, November 20th, Doug Janzen purchased 115,000 shares of Aequus Pharmaceuticals stock. The stock was bought at an average price of C$0.03 per share, with a total value of C$3,450.00.
- 11月20日，星期日，道格·詹森购买了11.5万股Aequus制药公司的股票。该股是以每股0.03加元的平均价格购买的，总价值为3,450.00加元。
Aequus Pharmaceuticals Stock Performance
Aequus制药公司股票表现
Shares of AQS remained flat at C$0.03 during trading hours on Wednesday. 409,000 shares of the stock were exchanged, compared to its average volume of 64,529. The firm has a 50-day moving average of C$0.04 and a 200 day moving average of C$0.06. The company has a quick ratio of 0.70, a current ratio of 0.78 and a debt-to-equity ratio of 138.88. The stock has a market capitalization of C$3.98 million and a P/E ratio of -2.69. Aequus Pharmaceuticals Inc. has a 1-year low of C$0.02 and a 1-year high of C$0.12.
在周三的交易时段，AQS的股价持平于0.03加元。该股成交量为40.9万股，而其平均成交量为64,529股。该公司的50日移动均线切入位在0.04加元，200日移动均线切入位在0.06加元。该公司的速动比率为0.70%，流动比率为0.78%，债务权益比率为138.88。该股市值为398万加元，市盈率为-2.69倍。Aequus PharmPharmticals Inc.的股价跌至0.02加元的一年低点和0.12加元的一年高点。
About Aequus Pharmaceuticals
Aequus制药公司简介
(Get Rating)
(获取评级)
Aequus Pharmaceuticals Inc, a specialty pharmaceutical company, develops and commercializes drugs in Canada. It focuses on various therapeutic areas, including neurology, ophthalmology, and transplantation. The company markets Vistitan, an ophthalmology product to reduce elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Tacrolimus IR, an immunosuppressant for the treatment and prevention of acute rejection following organ transplantation; Evolve dry eye products for various symptoms involved with dry eye disease and blepharitis, including discomfort, stinging, burning, and dryness; and preservative free ophthalmic product.
Aequus制药公司是一家专业制药公司，在加拿大开发和销售药物。它专注于各种治疗领域，包括神经学、眼科和移植。该公司销售Vistian，这是一种眼科产品，用于降低开角型青光眼或高眼压患者的高眼压；他克莫司IR，一种治疗和预防器官移植后急性排斥反应的免疫抑制剂；针对干眼病和眼缘炎的各种症状，包括不适、刺痛、灼热和干燥，开发干眼产品；以及不含防腐剂的眼科产品。
Featured Articles
专题文章
- Santa Claus Rally? Here's What Needs to Happen
- Cosmos Holdings May be a Long-Term Buy with Short-Term Risk
- Dark Clouds Are Gathering For Cloud Stocks
- Hormel: Is This The Time To Buy?
- 3 Dividend Growers With Good 2023 Growth Prospects
- 圣诞老人拉力赛？以下是需要发生的事情
- Cosmos Holdings可能是具有短期风险的长期买入
- 乌云云集，云股云集
- 霍梅尔：现在是买进的时候吗？
- 3个具有良好2023年增长前景的股息增长者
Receive News & Ratings for Aequus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aequus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
获得Aequus PharmPharmticals Daily的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Aequus制药和相关公司的最新新闻和分析师评级的每日简要摘要。